The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.
Peter Galle, M.D., Ph.D
Advertisement
Articles by Peter Galle, M.D., Ph.D
Advertisement
Latest Updated Articles
Patient-Reported Outcomes Improve with Combination Treatment for Some Patients With Hepatocellular CarcinomaPublished: January 30th 2020 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Helping Patients Understand the Evolving Landscape of Kidney Cancer Treatment
2
What Newly Diagnosed Patients Need to Know About Stage 2 Melanoma
3
Finding Hope Amidst a Lung Cancer Diagnosis
4
Survivorship and the Power of Community in Breast Cancer Awareness
5
